Kohsaku Ohnishi

Dr. Kohsaku Ohnishi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
EKEiji Kimura
Eiji Kimura
SASumiko Abe
Sumiko Abe
TTTakashi Tanimoto
Takashi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dL.

22 October 2018 in Preprints.org
Verified
Preprint
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
EKEiji Kimura
Eiji Kimura
SASumiko Abe
Sumiko Abe
TTTakashi Tanimoto
Takashi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
Background and Aim: Zinc plays a pivotal role in various zinc enzymes, resulting in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. It remains unknown whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development. Patients and Methods: Two hundred sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients) were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Results: Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p<0.001). According to the serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dl (p<0.001). Conclusion: Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dl.

11 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NHNaoko Hayata
Naoko Hayata
AHAtsushi Hosui
Atsushi Hosui
TKTomohide Kurahashi
Tomohide Kurahashi
SSShigeki Suemura
Shigeki Suemura
ANAkane Namiki
Akane Namiki
NHNaoki Hiramatsu
Naoki Hiramatsu
Background: Liver function is a critical factor, both in the selection of treatment and in the prediction of prognosis in patients with hepatocellular carcinoma (HCC). The ALBI grade, introduced as a more objective method of assessing liver function, utilizes serum albumin (Alb) and total bilirubin (Bil) levels. Although albumin is widely recognized for its role in maintaining colloid osmotic pressure and regulating plasma volume, recent studies have implicated it in tumor progression, invasion, and metastasis. The purpose of this study is to determine the impact of serum albumin levels on overall survival (OS) and tumor invasion/metastasis in HCC patients with the same liver function (ALBI grade) at the time of diagnosis. Methods: In this study, 285 patients diagnosed with primary HCC at our institution from 2015 to 2019 were classified by ALBI grade and analyzed. Among them, 78 patients with ALBI grade 2 status were selected to evaluate the impact of albumin level. To further isolate the effect of albumin rather than bilirubin, patients in the ALBI grade 2 cohort were divided into two groups based on mean values of Alb (3.5 g/dL) and Bil (1.0 mg/dL). Alb normal group (Group A): Alb ≥ 3.5 g/dL, Bil ≥ 1.0 mg/dL (n = 42). Bil normal group (Group T): Alb < 3.5 g/dL, Bil < 1.0 mg/dL (n = 36). Liver function was almost the same in these two groups based on the ALBI grade. OS, progression-free survival (PFS), types of recurrence, and pathological findings were compared between the two groups. OS was analyzed by the log-rank test, and comparisons between the two groups were performed by the t-test and chi-square test, with p < 0.05 indicating statistical significance. Results: OS was significantly worse in Group T than in Group A before and after propensity score matching based on age, performance status, and HCC stage (p < 0.001 and p = 0.011). Among the 44 patients who received curative treatment (surgery or radiofrequency ablation), OS was also significantly worse in Group T (p < 0.001). An analysis of the recurrence patterns of 44 curatively treated patients revealed that Group T had significantly shorter PFS (p < 0.001), and all recurrence patterns were multiple (p = 0.002). Pathological analysis in 28 surgical patients showed that serosal invasion was present in significantly more patients in Group T (p = 0.003). Conclusions: Low serum albumin levels in patients with HCC indicate both liver dysfunction and increased tumor invasion and metastasis. Nutritional support and albumin supplementation may help reduce intrahepatic metastases and improve prognosis. Further studies are needed to explore the underlying mechanisms and therapeutic potential.

14 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
TTTAKAFUMI TANIMOTO
TAKAFUMI TANIMOTO
TOToru Okahara
Toru Okahara
MAMunehiro Ashida
Munehiro Ashida
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal function was significantly milder in the tolvaptan group than in the conventional therapy group. The prognostic factors for survival in the tolvaptan group were being male, having hyperbilirubinemia, having a high blood urea nitrogen (BUN), and receiving high-dose furosemide at the start of tolvaptan treatment. The one-year and three-year cumulative survival rates were 67.8 and 45.3%, respectively, in patients with low-dose furosemide (<40 mg/day) at the start of tolvaptan treatment. The prognosis was significantly better in the tolvaptan group with low-dose furosemide than in the conventional therapy group (p < 0.001). (4) Conclusion: Tolvaptan can improve survival in patients with cirrhotic ascites, especially when tolvaptan is started before high-dose furosemide administration.

8 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
NHNaoko Hayata
Naoko Hayata
TKTomohide Kurahashi
Tomohide Kurahashi
ANAkane Namiki
Akane Namiki
AOAkino Okamoto
Akino Okamoto
NHNaoki Hiramatsu
Naoki Hiramatsu
Background/Objectives: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. Methods: One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria. SD patients whose initial antitumor effect was achieved received locoregional therapy, and the overall survival (OS) rate was assessed. Results: This study included 58 ATZ/BEV-treated participants and 47 LEN-treated participants. Twenty-eight SD patients (ATZ/BEV) and 20 SD patients (LEN) were identified. OS was significantly greater in ATZ/BEV-treated patients who also received locoregional therapy than in those who did not receive this additional therapy (p = 0.0343), whereas there was no difference between LEN-treated patients who also received locoregional therapy and those who did not. The locoregional therapy consisted of transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). When assessing the add-on effect of TACE and/or RFA in the SD patients treated with ATZ/BEV, five patients were found to achieve CR. Conclusions: The addition of locoregional therapy, such as TACE/RFA, was found to affect SD patients. When a response is limited during ATZ/BEV therapy, it is important to consider the therapeutic option of adding locoregional therapy, as this additional treatment may contribute to improved prognosis via immune modulation.

31 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TTTakafumi Tanimoto
Takafumi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
YIYuki Ito
Yuki Ito
YKYuhiko Katanosaka
Yuhiko Katanosaka
NHNaoko Hayata
Naoko Hayata
AHAtsushi Hosui
Atsushi Hosui
Background: Mechanical lithotripsy is used for difficult common bile duct (CBD) stones, but failure to fragment a grasped stone can complicate endoscopic management. Evidence regarding the association between preprocedural computed tomography (CT) attenuation and mechanical lithotripsy outcome is limited. This study explored the association between CT attenuation of CBD stones and mechanical basket lithotripsy failure in a single-centre retrospective cohort. Methods: We retrospectively analysed 37 patients in whom a CBD stone was grasped with a basket catheter, could not be extracted directly, and underwent attempted intraductal mechanical crushing between 1 April 2017 and 31 March 2023. Lithotripsy failure was defined as inability to fragment the grasped stone despite use of a dedicated crusher handle. Continuous variables were compared using the Mann–Whitney U test and categorical variables using Fisher’s exact test. CT attenuation analyses were restricted to CT-positive stones with measurable attenuation values (n = 27). Exploratory receiver operating characteristic (ROC) analyses were performed, and areas under the curve (AUCs) were accompanied by nonparametric bootstrap 95% confidence intervals (CIs) based on 10,000 resamples. No clinical CT attenuation threshold was proposed. Results: Mechanical lithotripsy succeeded in 31 patients and failed in 6. CT attenuation was measurable in 27 patients (21 successes and 6 failures). Among these patients, the failure group had higher mean CT attenuation than the success group (median 241 [IQR 217.8–473.5] HU vs. 76 [67–88] HU; p = 0.00064) and higher maximum CT attenuation (386 [269.8–589.3] HU vs. 123 [102–133] HU; p = 0.00133). Exploratory ROC analysis showed an AUC of 0.968 (bootstrap 95% CI, 0.871–1.000) for mean CT attenuation and 0.940 (bootstrap 95% CI, 0.800–1.000) for maximum CT attenuation. These estimates were derived and evaluated in the same small dataset and were therefore considered exploratory. Conclusions: In this small, selected retrospective cohort, higher CT attenuation values were observed among the six patients with mechanical basket lithotripsy failure. These findings are exploratory and require confirmation in larger prospective studies using standardized CT protocols before CT attenuation can be incorporated into procedural decision-making.